Veteran investment executive with experience in private equity and corporate finance, focused on growth-stage technology and healthcare investments. Joseph Morrison was previously a partner at a mid-market PE firm and has led cross-border M&A, portfolio operational turnarounds, and value-creation programs. Holds an MBA with earlier investment banking experience; active board member emphasising EBITDA improvement, capital-structure optimization and disciplined exit planning.
Veteran investment executive with experience in private equity and corporate finance, focused on growth-stage technology and healthcare investments. Joseph Morrison was previously a partner at a mid-market PE firm and has led cross-border M&A, portfolio operational turnarounds, and value-creation programs. Holds an MBA with earlier investment banking experience; active board member emphasising EBITDA improvement, capital-structure optimization and disciplined exit planning.
Brings a private-equity mindset to growth-stage technology and healthcare investing, prioritizing companies with durable unit economics and clear pathways to EBITDA improvement. Focuses on hands-on value creation—operational turnarounds, go-to-market scaling and capital‑structure optimization—combined with disciplined underwriting and exit planning. Leverages cross-border M&A and corporate‑finance experience to structure flexible, mid‑to‑long horizon investments that balance revenue growth with margin restoration. Prefers control or influential minority positions where board-level intervention can accelerate operational change and de‑risk outcomes.
Brings a private-equity mindset to growth-stage technology and healthcare investing, prioritizing companies with durable unit economics and clear pathways to EBITDA improvement. Focuses on hands-on value creation—operational turnarounds, go-to-market scaling and capital‑structure optimization—combined with disciplined underwriting and exit planning. Leverages cross-border M&A and corporate‑finance experience to structure flexible, mid‑to‑long horizon investments that balance revenue growth with margin restoration. Prefers control or influential minority positions where board-level intervention can accelerate operational change and de‑risk outcomes.
| Trades 765 | Longs Won 561/765 73% | Profit Factor 29.53 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $5.72M |
| Average Win $660,588.1 | Best Trade (Mar 31) $140.19M | Sharpe Ratio -27.55 |
| Average Loss -$61,525.37 | Worst Trade (Sep 30) -$6.79M | Z-Score 12.06 (100%) |
| Commissions $0 | Avg. Trade Length 1y 9m 2w 4d | Expectancy $467,487.37 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | 0.02% | 0.15% | 0.84% | 3.55% | 12.4% | 37.32% |
| Consecutive Losing Trades | 5,376 | 4,839 | 4,301 | 3,763 | 3,226 | 2,688 | 2,151 | 1,613 | 1,075 | 538 |